nodes	percent_of_prediction	percent_of_DWPC	metapath
Amsacrine—TOP2A—Valrubicin—urinary bladder cancer	0.484	0.661	CbGbCtD
Amsacrine—TOP2A—Epirubicin—urinary bladder cancer	0.0733	0.1	CbGbCtD
Amsacrine—TOP2A—Etoposide—urinary bladder cancer	0.0571	0.0781	CbGbCtD
Amsacrine—TOP2A—Doxorubicin—urinary bladder cancer	0.0389	0.0532	CbGbCtD
Amsacrine—ABCB1—Mitomycin—urinary bladder cancer	0.0372	0.0508	CbGbCtD
Amsacrine—ABCB1—Gemcitabine—urinary bladder cancer	0.0107	0.0146	CbGbCtD
Amsacrine—ABCB1—Cisplatin—urinary bladder cancer	0.00777	0.0106	CbGbCtD
Amsacrine—ABCB1—Etoposide—urinary bladder cancer	0.00764	0.0104	CbGbCtD
Amsacrine—ABCB1—Doxorubicin—urinary bladder cancer	0.00521	0.00712	CbGbCtD
Amsacrine—ABCB1—Methotrexate—urinary bladder cancer	0.00505	0.0069	CbGbCtD
Amsacrine—CYP2D6—Doxorubicin—urinary bladder cancer	0.00491	0.00671	CbGbCtD
Amsacrine—NCOA3—prostate gland—urinary bladder cancer	0.00412	0.117	CbGeAlD
Amsacrine—NCOA3—smooth muscle tissue—urinary bladder cancer	0.00292	0.0828	CbGeAlD
Amsacrine—NCOA3—renal system—urinary bladder cancer	0.00281	0.0797	CbGeAlD
Amsacrine—NCOA3—urethra—urinary bladder cancer	0.00276	0.0783	CbGeAlD
Amsacrine—TOP2A—prostate gland—urinary bladder cancer	0.00242	0.0686	CbGeAlD
Amsacrine—CYP2D6—urine—urinary bladder cancer	0.0023	0.0653	CbGeAlD
Amsacrine—NCOA3—female reproductive system—urinary bladder cancer	0.00225	0.0639	CbGeAlD
Amsacrine—NCOA3—vagina—urinary bladder cancer	0.00203	0.0578	CbGeAlD
Amsacrine—NCOA3—Idarubicin—Valrubicin—urinary bladder cancer	0.00181	0.361	CbGdCrCtD
Amsacrine—KCNH2—prostate gland—urinary bladder cancer	0.00135	0.0385	CbGeAlD
Amsacrine—NCOA3—lymph node—urinary bladder cancer	0.00132	0.0374	CbGeAlD
Amsacrine—TOP2A—vagina—urinary bladder cancer	0.00119	0.0339	CbGeAlD
Amsacrine—KCNH2—seminal vesicle—urinary bladder cancer	0.00115	0.0325	CbGeAlD
Amsacrine—KCNH2—renal system—urinary bladder cancer	0.000923	0.0262	CbGeAlD
Amsacrine—KCNH2—urethra—urinary bladder cancer	0.000907	0.0257	CbGeAlD
Amsacrine—TOP2A—lymph node—urinary bladder cancer	0.000772	0.0219	CbGeAlD
Amsacrine—KCNH2—female reproductive system—urinary bladder cancer	0.000739	0.021	CbGeAlD
Amsacrine—KCNH2—vagina—urinary bladder cancer	0.000669	0.019	CbGeAlD
Amsacrine—NCOA3—Idarubicin—Epirubicin—urinary bladder cancer	0.00063	0.126	CbGdCrCtD
Amsacrine—ABCB1—prostate gland—urinary bladder cancer	0.000594	0.0169	CbGeAlD
Amsacrine—NCOA3—Idarubicin—Doxorubicin—urinary bladder cancer	0.000583	0.116	CbGdCrCtD
Amsacrine—CYP2D6—renal system—urinary bladder cancer	0.000563	0.016	CbGeAlD
Amsacrine—ABCB1—seminal vesicle—urinary bladder cancer	0.000502	0.0143	CbGeAlD
Amsacrine—CYP2D6—female reproductive system—urinary bladder cancer	0.000451	0.0128	CbGeAlD
Amsacrine—ABCB1—epithelium—urinary bladder cancer	0.000437	0.0124	CbGeAlD
Amsacrine—KCNH2—lymph node—urinary bladder cancer	0.000432	0.0123	CbGeAlD
Amsacrine—ABCB1—renal system—urinary bladder cancer	0.000405	0.0115	CbGeAlD
Amsacrine—ABCB1—urethra—urinary bladder cancer	0.000398	0.0113	CbGeAlD
Amsacrine—ABCB1—female reproductive system—urinary bladder cancer	0.000324	0.00921	CbGeAlD
Amsacrine—ABCB1—vagina—urinary bladder cancer	0.000293	0.00833	CbGeAlD
Amsacrine—TOP2A—Doxorubicin—Valrubicin—urinary bladder cancer	0.000249	0.0496	CbGdCrCtD
Amsacrine—TOP2A—Idarubicin—Valrubicin—urinary bladder cancer	0.000249	0.0496	CbGdCrCtD
Amsacrine—TOP2A—Daunorubicin—Valrubicin—urinary bladder cancer	0.000249	0.0496	CbGdCrCtD
Amsacrine—TOP2A—Epirubicin—Valrubicin—urinary bladder cancer	0.000249	0.0496	CbGdCrCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	0.000242	0.00347	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—GSTO2—urinary bladder cancer	0.000236	0.00338	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—NAT1—urinary bladder cancer	0.000236	0.00338	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000232	0.00333	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—ERBB2—urinary bladder cancer	0.000226	0.00324	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CDK4—urinary bladder cancer	0.000222	0.0032	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.000221	0.00318	CbGpPWpGaD
Amsacrine—TOP2A—Gastric Cancer Network 2—TP53—urinary bladder cancer	0.000216	0.0031	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—UGT2B7—urinary bladder cancer	0.000216	0.0031	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—CCND1—urinary bladder cancer	0.000211	0.00303	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CCNE1—urinary bladder cancer	0.000204	0.00294	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—ESPL1—urinary bladder cancer	0.000204	0.00293	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—PTEN—urinary bladder cancer	0.000203	0.00292	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—TYMS—urinary bladder cancer	0.000201	0.00288	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000198	0.00284	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000195	0.0028	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	0.000195	0.0028	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—CYP4B1—urinary bladder cancer	0.000194	0.00279	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—EP300—urinary bladder cancer	0.000194	0.00279	CbGpPWpGaD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—RB1—urinary bladder cancer	0.000193	0.00278	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—PTEN—urinary bladder cancer	0.000192	0.00276	CbGpPWpGaD
Amsacrine—ABCB1—lymph node—urinary bladder cancer	0.00019	0.00539	CbGeAlD
Amsacrine—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000187	0.00269	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000187	0.00269	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000185	0.00266	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—SLC19A1—urinary bladder cancer	0.000183	0.00263	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—ESPL1—urinary bladder cancer	0.000182	0.00262	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PRSS3—urinary bladder cancer	0.000179	0.00256	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—SRC—urinary bladder cancer	0.000178	0.00256	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000171	0.00246	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—TFRC—urinary bladder cancer	0.00017	0.00245	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000169	0.00243	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—MYC—urinary bladder cancer	0.000169	0.00243	CbGpPWpGaD
Amsacrine—NCOA3—Fatty acid, triacylglycerol, and ketone body metabolism—EP300—urinary bladder cancer	0.000169	0.00242	CbGpPWpGaD
Amsacrine—TOP2A—Podofilox—Etoposide—urinary bladder cancer	0.000166	0.0331	CbGdCrCtD
Amsacrine—TOP2A—Teniposide—Etoposide—urinary bladder cancer	0.000166	0.0331	CbGdCrCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—EGFR—urinary bladder cancer	0.000165	0.00238	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—NCOR1—urinary bladder cancer	0.00016	0.0023	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDK4—urinary bladder cancer	0.000157	0.00225	CbGpPWpGaD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—EGFR—urinary bladder cancer	0.000156	0.00225	CbGpPWpGaD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—KRAS—urinary bladder cancer	0.000156	0.00224	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	0.000155	0.00222	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—STAG2—urinary bladder cancer	0.000154	0.00222	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—LIG1—urinary bladder cancer	0.000154	0.00222	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000154	0.00222	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000152	0.00219	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	0.000152	0.00218	CbGpPWpGaD
Amsacrine—Dyspnoea—Fluorouracil—urinary bladder cancer	0.000148	0.000931	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—KRAS—urinary bladder cancer	0.000148	0.00212	CbGpPWpGaD
Amsacrine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.000148	0.00093	CcSEcCtD
Amsacrine—Hypotension—Cisplatin—urinary bladder cancer	0.000147	0.000925	CcSEcCtD
Amsacrine—Decreased appetite—Gemcitabine—urinary bladder cancer	0.000146	0.000923	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—TYMS—urinary bladder cancer	0.000146	0.0021	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Gemcitabine—urinary bladder cancer	0.000145	0.000917	CcSEcCtD
Amsacrine—Fatigue—Gemcitabine—urinary bladder cancer	0.000145	0.000916	CcSEcCtD
Amsacrine—Confusional state—Etoposide—urinary bladder cancer	0.000145	0.000915	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—NCOR1—urinary bladder cancer	0.000144	0.00207	CbGpPWpGaD
Amsacrine—Pain—Gemcitabine—urinary bladder cancer	0.000144	0.000908	CcSEcCtD
Amsacrine—Decreased appetite—Fluorouracil—urinary bladder cancer	0.000144	0.000908	CcSEcCtD
Amsacrine—Pancytopenia—Methotrexate—urinary bladder cancer	0.000144	0.000907	CcSEcCtD
Amsacrine—Mood swings—Doxorubicin—urinary bladder cancer	0.000144	0.000907	CcSEcCtD
Amsacrine—Asthenia—Thiotepa—urinary bladder cancer	0.000144	0.000906	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CCND1—urinary bladder cancer	0.000144	0.00206	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000143	0.00206	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Fluorouracil—urinary bladder cancer	0.000143	0.000902	CcSEcCtD
Amsacrine—Infection—Etoposide—urinary bladder cancer	0.000143	0.000901	CcSEcCtD
Amsacrine—NCOA3—Metabolism—TYMP—urinary bladder cancer	0.000143	0.00205	CbGpPWpGaD
Amsacrine—Blood creatinine increased—Doxorubicin—urinary bladder cancer	0.000142	0.000897	CcSEcCtD
Amsacrine—Dysphagia—Epirubicin—urinary bladder cancer	0.000142	0.000894	CcSEcCtD
Amsacrine—Pain—Fluorouracil—urinary bladder cancer	0.000142	0.000893	CcSEcCtD
Amsacrine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000141	0.00203	CbGpPWpGaD
Amsacrine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000141	0.000889	CcSEcCtD
Amsacrine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000141	0.000888	CcSEcCtD
Amsacrine—Tachycardia—Etoposide—urinary bladder cancer	0.00014	0.000885	CcSEcCtD
Amsacrine—Dyspnoea—Cisplatin—urinary bladder cancer	0.00014	0.000883	CcSEcCtD
Amsacrine—Skin disorder—Etoposide—urinary bladder cancer	0.00014	0.000881	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—CDKN1A—urinary bladder cancer	0.000139	0.002	CbGpPWpGaD
Amsacrine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.000139	0.000875	CcSEcCtD
Amsacrine—NCOA3—Integrated Breast Cancer Pathway—TP53—urinary bladder cancer	0.000139	0.00199	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—LIG1—urinary bladder cancer	0.000138	0.00198	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—STAG2—urinary bladder cancer	0.000138	0.00198	CbGpPWpGaD
Amsacrine—Anorexia—Etoposide—urinary bladder cancer	0.000137	0.000865	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000137	0.00197	CbGpPWpGaD
Amsacrine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000137	0.000864	CcSEcCtD
Amsacrine—Aspartate aminotransferase increased—Doxorubicin—urinary bladder cancer	0.000137	0.000862	CcSEcCtD
Amsacrine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000137	0.000861	CcSEcCtD
Amsacrine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000137	0.000861	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—RB1—urinary bladder cancer	0.000136	0.00195	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Cisplatin—urinary bladder cancer	0.000136	0.000855	CcSEcCtD
Amsacrine—Infestation—Methotrexate—urinary bladder cancer	0.000135	0.000852	CcSEcCtD
Amsacrine—Infestation NOS—Methotrexate—urinary bladder cancer	0.000135	0.000852	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	0.000135	0.00194	CbGpPWpGaD
Amsacrine—Pancytopenia—Epirubicin—urinary bladder cancer	0.000135	0.000849	CcSEcCtD
Amsacrine—Hypotension—Etoposide—urinary bladder cancer	0.000134	0.000848	CcSEcCtD
Amsacrine—Pain—Cisplatin—urinary bladder cancer	0.000134	0.000847	CcSEcCtD
Amsacrine—Body temperature increased—Gemcitabine—urinary bladder cancer	0.000133	0.00084	CcSEcCtD
Amsacrine—Renal failure—Methotrexate—urinary bladder cancer	0.000133	0.000837	CcSEcCtD
Amsacrine—Dizziness—Thiotepa—urinary bladder cancer	0.000132	0.000835	CcSEcCtD
Amsacrine—Stomatitis—Methotrexate—urinary bladder cancer	0.000132	0.00083	CcSEcCtD
Amsacrine—Urticaria—Fluorouracil—urinary bladder cancer	0.000132	0.00083	CcSEcCtD
Amsacrine—Dysphagia—Doxorubicin—urinary bladder cancer	0.000131	0.000827	CcSEcCtD
Amsacrine—Body temperature increased—Fluorouracil—urinary bladder cancer	0.000131	0.000826	CcSEcCtD
Amsacrine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000129	0.000816	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—FAS—urinary bladder cancer	0.000129	0.00186	CbGpPWpGaD
Amsacrine—Paraesthesia—Etoposide—urinary bladder cancer	0.000129	0.000814	CcSEcCtD
Amsacrine—NCOA3—Metabolism—NAT2—urinary bladder cancer	0.000129	0.00185	CbGpPWpGaD
Amsacrine—Weight increased—Epirubicin—urinary bladder cancer	0.000129	0.000814	CcSEcCtD
Amsacrine—Haematuria—Methotrexate—urinary bladder cancer	0.000129	0.000812	CcSEcCtD
Amsacrine—Weight decreased—Epirubicin—urinary bladder cancer	0.000128	0.000809	CcSEcCtD
Amsacrine—Dyspnoea—Etoposide—urinary bladder cancer	0.000128	0.000809	CcSEcCtD
Amsacrine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.000128	0.000806	CcSEcCtD
Amsacrine—Vomiting—Thiotepa—urinary bladder cancer	0.000127	0.000803	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—RRM2—urinary bladder cancer	0.000127	0.00183	CbGpPWpGaD
Amsacrine—Infestation—Epirubicin—urinary bladder cancer	0.000126	0.000797	CcSEcCtD
Amsacrine—Infestation NOS—Epirubicin—urinary bladder cancer	0.000126	0.000797	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—CDK4—urinary bladder cancer	0.000126	0.00182	CbGpPWpGaD
Amsacrine—Rash—Thiotepa—urinary bladder cancer	0.000126	0.000796	CcSEcCtD
Amsacrine—Dermatitis—Thiotepa—urinary bladder cancer	0.000126	0.000795	CcSEcCtD
Amsacrine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000126	0.000795	CcSEcCtD
Amsacrine—NCOA3—EGF/EGFR Signaling Pathway—HRAS—urinary bladder cancer	0.000126	0.0018	CbGpPWpGaD
Amsacrine—Headache—Thiotepa—urinary bladder cancer	0.000125	0.000791	CcSEcCtD
Amsacrine—Decreased appetite—Etoposide—urinary bladder cancer	0.000125	0.000788	CcSEcCtD
Amsacrine—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000125	0.000786	CcSEcCtD
Amsacrine—Renal failure—Epirubicin—urinary bladder cancer	0.000124	0.000784	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Etoposide—urinary bladder cancer	0.000124	0.000783	CcSEcCtD
Amsacrine—Body temperature increased—Cisplatin—urinary bladder cancer	0.000124	0.000783	CcSEcCtD
Amsacrine—Fatigue—Etoposide—urinary bladder cancer	0.000124	0.000782	CcSEcCtD
Amsacrine—Jaundice—Epirubicin—urinary bladder cancer	0.000123	0.000777	CcSEcCtD
Amsacrine—Stomatitis—Epirubicin—urinary bladder cancer	0.000123	0.000777	CcSEcCtD
Amsacrine—Pain—Etoposide—urinary bladder cancer	0.000123	0.000776	CcSEcCtD
Amsacrine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000122	0.000769	CcSEcCtD
Amsacrine—Haemoglobin—Methotrexate—urinary bladder cancer	0.000122	0.000769	CcSEcCtD
Amsacrine—Haemorrhage—Methotrexate—urinary bladder cancer	0.000121	0.000765	CcSEcCtD
Amsacrine—Hepatitis—Methotrexate—urinary bladder cancer	0.000121	0.000765	CcSEcCtD
Amsacrine—Asthenia—Gemcitabine—urinary bladder cancer	0.000121	0.000762	CcSEcCtD
Amsacrine—Haematuria—Epirubicin—urinary bladder cancer	0.000121	0.00076	CcSEcCtD
Amsacrine—Urinary tract disorder—Methotrexate—urinary bladder cancer	0.00012	0.000755	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN2A—urinary bladder cancer	0.00012	0.00172	CbGpPWpGaD
Amsacrine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.00012	0.000754	CcSEcCtD
Amsacrine—Weight increased—Doxorubicin—urinary bladder cancer	0.000119	0.000753	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	0.000119	0.00171	CbGpPWpGaD
Amsacrine—Nausea—Thiotepa—urinary bladder cancer	0.000119	0.00075	CcSEcCtD
Amsacrine—Urethral disorder—Methotrexate—urinary bladder cancer	0.000119	0.00075	CcSEcCtD
Amsacrine—Weight decreased—Doxorubicin—urinary bladder cancer	0.000119	0.000748	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	0.000119	0.0017	CbGpPWpGaD
Amsacrine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000119	0.000747	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	0.000118	0.0017	CbGpPWpGaD
Amsacrine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000118	0.000744	CcSEcCtD
Amsacrine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.000118	0.000742	CcSEcCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000118	0.00169	CbGpPWpGaD
Amsacrine—Infestation NOS—Doxorubicin—urinary bladder cancer	0.000117	0.000738	CcSEcCtD
Amsacrine—Infestation—Doxorubicin—urinary bladder cancer	0.000117	0.000738	CcSEcCtD
Amsacrine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.000116	0.000729	CcSEcCtD
Amsacrine—Bradycardia—Epirubicin—urinary bladder cancer	0.000116	0.000729	CcSEcCtD
Amsacrine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000115	0.000727	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—MYC—urinary bladder cancer	0.000115	0.00165	CbGpPWpGaD
Amsacrine—Renal failure—Doxorubicin—urinary bladder cancer	0.000115	0.000725	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—PPARG—urinary bladder cancer	0.000115	0.00165	CbGpPWpGaD
Amsacrine—Urticaria—Etoposide—urinary bladder cancer	0.000114	0.000721	CcSEcCtD
Amsacrine—Haemoglobin—Epirubicin—urinary bladder cancer	0.000114	0.000719	CcSEcCtD
Amsacrine—Jaundice—Doxorubicin—urinary bladder cancer	0.000114	0.000719	CcSEcCtD
Amsacrine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000114	0.000719	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—CDK4—urinary bladder cancer	0.000114	0.00164	CbGpPWpGaD
Amsacrine—Abdominal pain—Etoposide—urinary bladder cancer	0.000114	0.000717	CcSEcCtD
Amsacrine—Body temperature increased—Etoposide—urinary bladder cancer	0.000114	0.000717	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—RRM2—urinary bladder cancer	0.000114	0.00163	CbGpPWpGaD
Amsacrine—Hepatitis—Epirubicin—urinary bladder cancer	0.000114	0.000716	CcSEcCtD
Amsacrine—Haemorrhage—Epirubicin—urinary bladder cancer	0.000114	0.000716	CcSEcCtD
Amsacrine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000113	0.000715	CcSEcCtD
Amsacrine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000113	0.000712	CcSEcCtD
Amsacrine—Asthenia—Cisplatin—urinary bladder cancer	0.000113	0.00071	CcSEcCtD
Amsacrine—Cardiac disorder—Methotrexate—urinary bladder cancer	0.000113	0.00071	CcSEcCtD
Amsacrine—Urinary tract disorder—Epirubicin—urinary bladder cancer	0.000112	0.000707	CcSEcCtD
Amsacrine—Haematuria—Doxorubicin—urinary bladder cancer	0.000112	0.000703	CcSEcCtD
Amsacrine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000112	0.000703	CcSEcCtD
Amsacrine—NCOA3—Metabolism—RRM2—urinary bladder cancer	0.000111	0.0016	CbGpPWpGaD
Amsacrine—Urethral disorder—Epirubicin—urinary bladder cancer	0.000111	0.000701	CcSEcCtD
Amsacrine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000111	0.000698	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—CREBBP—urinary bladder cancer	0.00011	0.00159	CbGpPWpGaD
Amsacrine—Angiopathy—Methotrexate—urinary bladder cancer	0.00011	0.000694	CcSEcCtD
Amsacrine—Dizziness—Fluorouracil—urinary bladder cancer	0.00011	0.000691	CcSEcCtD
Amsacrine—Mediastinal disorder—Methotrexate—urinary bladder cancer	0.000109	0.000689	CcSEcCtD
Amsacrine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000109	0.000688	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—SMC1A—urinary bladder cancer	0.000108	0.00155	CbGpPWpGaD
Amsacrine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000107	0.000677	CcSEcCtD
Amsacrine—Alopecia—Methotrexate—urinary bladder cancer	0.000107	0.000676	CcSEcCtD
Amsacrine—Vomiting—Gemcitabine—urinary bladder cancer	0.000107	0.000675	CcSEcCtD
Amsacrine—Bradycardia—Doxorubicin—urinary bladder cancer	0.000107	0.000674	CcSEcCtD
Amsacrine—Mental disorder—Methotrexate—urinary bladder cancer	0.000106	0.00067	CcSEcCtD
Amsacrine—Rash—Gemcitabine—urinary bladder cancer	0.000106	0.00067	CcSEcCtD
Amsacrine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000106	0.000669	CcSEcCtD
Amsacrine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000106	0.000668	CcSEcCtD
Amsacrine—Malnutrition—Methotrexate—urinary bladder cancer	0.000106	0.000666	CcSEcCtD
Amsacrine—Haemoglobin—Doxorubicin—urinary bladder cancer	0.000106	0.000666	CcSEcCtD
Amsacrine—Headache—Gemcitabine—urinary bladder cancer	0.000106	0.000665	CcSEcCtD
Amsacrine—Cardiac disorder—Epirubicin—urinary bladder cancer	0.000105	0.000664	CcSEcCtD
Amsacrine—Vomiting—Fluorouracil—urinary bladder cancer	0.000105	0.000664	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—LIG1—urinary bladder cancer	0.000105	0.00151	CbGpPWpGaD
Amsacrine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000105	0.000662	CcSEcCtD
Amsacrine—Haemorrhage—Doxorubicin—urinary bladder cancer	0.000105	0.000662	CcSEcCtD
Amsacrine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000105	0.000659	CcSEcCtD
Amsacrine—Rash—Fluorouracil—urinary bladder cancer	0.000104	0.000658	CcSEcCtD
Amsacrine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000104	0.000658	CcSEcCtD
Amsacrine—Headache—Fluorouracil—urinary bladder cancer	0.000104	0.000654	CcSEcCtD
Amsacrine—Urinary tract disorder—Doxorubicin—urinary bladder cancer	0.000104	0.000654	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	0.000103	0.00149	CbGpPWpGaD
Amsacrine—TOP2A—Circadian rythm related genes—PPARG—urinary bladder cancer	0.000103	0.00149	CbGpPWpGaD
Amsacrine—Asthenia—Etoposide—urinary bladder cancer	0.000103	0.000651	CcSEcCtD
Amsacrine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000103	0.000651	CcSEcCtD
Amsacrine—NCOA3—Metabolism—HPGDS—urinary bladder cancer	0.000103	0.00148	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—ENO2—urinary bladder cancer	0.000103	0.00148	CbGpPWpGaD
Amsacrine—Angiopathy—Epirubicin—urinary bladder cancer	0.000103	0.000649	CcSEcCtD
Amsacrine—Urethral disorder—Doxorubicin—urinary bladder cancer	0.000103	0.000649	CcSEcCtD
Amsacrine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.000103	0.00148	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	0.000103	0.00147	CbGpPWpGaD
Amsacrine—Mediastinal disorder—Epirubicin—urinary bladder cancer	0.000102	0.000645	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	0.000102	0.00147	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—TERT—urinary bladder cancer	0.000102	0.00147	CbGpPWpGaD
Amsacrine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000101	0.000639	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000101	0.00145	CbGpPWpGaD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CCND1—urinary bladder cancer	0.000101	0.00145	CbGpPWpGaD
Amsacrine—Alopecia—Epirubicin—urinary bladder cancer	0.0001	0.000632	CcSEcCtD
Amsacrine—NCOA3—Metabolism—GSTT1—urinary bladder cancer	0.0001	0.00144	CbGpPWpGaD
Amsacrine—Nausea—Gemcitabine—urinary bladder cancer	0.0001	0.000631	CcSEcCtD
Amsacrine—Vomiting—Cisplatin—urinary bladder cancer	9.99e-05	0.000629	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—RHOA—urinary bladder cancer	9.99e-05	0.00143	CbGpPWpGaD
Amsacrine—Vision blurred—Methotrexate—urinary bladder cancer	9.95e-05	0.000627	CcSEcCtD
Amsacrine—Mental disorder—Epirubicin—urinary bladder cancer	9.95e-05	0.000627	CcSEcCtD
Amsacrine—Rash—Cisplatin—urinary bladder cancer	9.9e-05	0.000624	CcSEcCtD
Amsacrine—Dermatitis—Cisplatin—urinary bladder cancer	9.89e-05	0.000624	CcSEcCtD
Amsacrine—Malnutrition—Epirubicin—urinary bladder cancer	9.88e-05	0.000623	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.86e-05	0.00142	CbGpPWpGaD
Amsacrine—Diarrhoea—Etoposide—urinary bladder cancer	9.85e-05	0.000621	CcSEcCtD
Amsacrine—Nausea—Fluorouracil—urinary bladder cancer	9.84e-05	0.00062	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—CDKN1A—urinary bladder cancer	9.78e-05	0.0014	CbGpPWpGaD
Amsacrine—Anaemia—Methotrexate—urinary bladder cancer	9.76e-05	0.000615	CcSEcCtD
Amsacrine—Cardiac disorder—Doxorubicin—urinary bladder cancer	9.75e-05	0.000615	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—SMC1A—urinary bladder cancer	9.67e-05	0.00139	CbGpPWpGaD
Amsacrine—Angiopathy—Doxorubicin—urinary bladder cancer	9.53e-05	0.000601	CcSEcCtD
Amsacrine—Dizziness—Etoposide—urinary bladder cancer	9.52e-05	0.0006	CcSEcCtD
Amsacrine—Mediastinal disorder—Doxorubicin—urinary bladder cancer	9.47e-05	0.000597	CcSEcCtD
Amsacrine—TOP2A—Retinoblastoma (RB) in Cancer—TP53—urinary bladder cancer	9.46e-05	0.00136	CbGpPWpGaD
Amsacrine—Leukopenia—Methotrexate—urinary bladder cancer	9.45e-05	0.000596	CcSEcCtD
Amsacrine—Arrhythmia—Doxorubicin—urinary bladder cancer	9.38e-05	0.000592	CcSEcCtD
Amsacrine—TOP2A—Cytarabine—Gemcitabine—urinary bladder cancer	9.34e-05	0.0186	CbGdCrCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	9.33e-05	0.00134	CbGpPWpGaD
Amsacrine—Nausea—Cisplatin—urinary bladder cancer	9.33e-05	0.000588	CcSEcCtD
Amsacrine—Vision blurred—Epirubicin—urinary bladder cancer	9.31e-05	0.000587	CcSEcCtD
Amsacrine—Alopecia—Doxorubicin—urinary bladder cancer	9.28e-05	0.000585	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—ERBB2—urinary bladder cancer	9.24e-05	0.00133	CbGpPWpGaD
Amsacrine—Mental disorder—Doxorubicin—urinary bladder cancer	9.2e-05	0.00058	CcSEcCtD
Amsacrine—Convulsion—Methotrexate—urinary bladder cancer	9.15e-05	0.000577	CcSEcCtD
Amsacrine—Vomiting—Etoposide—urinary bladder cancer	9.15e-05	0.000577	CcSEcCtD
Amsacrine—Malnutrition—Doxorubicin—urinary bladder cancer	9.14e-05	0.000576	CcSEcCtD
Amsacrine—Anaemia—Epirubicin—urinary bladder cancer	9.13e-05	0.000576	CcSEcCtD
Amsacrine—Rash—Etoposide—urinary bladder cancer	9.07e-05	0.000572	CcSEcCtD
Amsacrine—Dermatitis—Etoposide—urinary bladder cancer	9.06e-05	0.000571	CcSEcCtD
Amsacrine—Headache—Etoposide—urinary bladder cancer	9.01e-05	0.000568	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—FAS—urinary bladder cancer	8.99e-05	0.00129	CbGpPWpGaD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—urinary bladder cancer	8.93e-05	0.000563	CcSEcCtD
Amsacrine—Leukopenia—Epirubicin—urinary bladder cancer	8.85e-05	0.000558	CcSEcCtD
Amsacrine—Confusional state—Methotrexate—urinary bladder cancer	8.69e-05	0.000548	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	8.67e-05	0.00124	CbGpPWpGaD
Amsacrine—TOP2A—Idarubicin—Epirubicin—urinary bladder cancer	8.66e-05	0.0173	CbGdCrCtD
Amsacrine—TOP2A—Doxorubicin—Epirubicin—urinary bladder cancer	8.66e-05	0.0173	CbGdCrCtD
Amsacrine—TOP2A—Daunorubicin—Epirubicin—urinary bladder cancer	8.66e-05	0.0173	CbGdCrCtD
Amsacrine—Vision blurred—Doxorubicin—urinary bladder cancer	8.62e-05	0.000543	CcSEcCtD
Amsacrine—Convulsion—Epirubicin—urinary bladder cancer	8.56e-05	0.00054	CcSEcCtD
Amsacrine—Infection—Methotrexate—urinary bladder cancer	8.56e-05	0.00054	CcSEcCtD
Amsacrine—Nausea—Etoposide—urinary bladder cancer	8.55e-05	0.000539	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	8.47e-05	0.00122	CbGpPWpGaD
Amsacrine—Anaemia—Doxorubicin—urinary bladder cancer	8.45e-05	0.000533	CcSEcCtD
Amsacrine—Thrombocytopenia—Methotrexate—urinary bladder cancer	8.44e-05	0.000532	CcSEcCtD
Amsacrine—Skin disorder—Methotrexate—urinary bladder cancer	8.37e-05	0.000528	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—urinary bladder cancer	8.36e-05	0.000527	CcSEcCtD
Amsacrine—NCOA3—Metabolism—NQO1—urinary bladder cancer	8.32e-05	0.00119	CbGpPWpGaD
Amsacrine—Anorexia—Methotrexate—urinary bladder cancer	8.22e-05	0.000518	CcSEcCtD
Amsacrine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	8.21e-05	0.00118	CbGpPWpGaD
Amsacrine—Leukopenia—Doxorubicin—urinary bladder cancer	8.19e-05	0.000516	CcSEcCtD
Amsacrine—Confusional state—Epirubicin—urinary bladder cancer	8.13e-05	0.000513	CcSEcCtD
Amsacrine—TOP2A—Mitotic G1-G1/S phases—MYC—urinary bladder cancer	8.11e-05	0.00116	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	8.07e-05	0.00116	CbGpPWpGaD
Amsacrine—Hypotension—Methotrexate—urinary bladder cancer	8.05e-05	0.000508	CcSEcCtD
Amsacrine—Infection—Epirubicin—urinary bladder cancer	8.01e-05	0.000505	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—HPGDS—urinary bladder cancer	8.01e-05	0.00115	CbGpPWpGaD
Amsacrine—TOP2A—Epirubicin—Doxorubicin—urinary bladder cancer	8.01e-05	0.016	CbGdCrCtD
Amsacrine—TOP2A—Idarubicin—Doxorubicin—urinary bladder cancer	8.01e-05	0.016	CbGdCrCtD
Amsacrine—TOP2A—Daunorubicin—Doxorubicin—urinary bladder cancer	8.01e-05	0.016	CbGdCrCtD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	8e-05	0.00115	CbGpPWpGaD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—CREBBP—urinary bladder cancer	7.97e-05	0.00115	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	7.96e-05	0.00114	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—IGFBP3—urinary bladder cancer	7.96e-05	0.00114	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—MMP9—urinary bladder cancer	7.93e-05	0.00114	CbGpPWpGaD
Amsacrine—Convulsion—Doxorubicin—urinary bladder cancer	7.92e-05	0.000499	CcSEcCtD
Amsacrine—Thrombocytopenia—Epirubicin—urinary bladder cancer	7.9e-05	0.000498	CcSEcCtD
Amsacrine—Tachycardia—Epirubicin—urinary bladder cancer	7.87e-05	0.000496	CcSEcCtD
Amsacrine—Skin disorder—Epirubicin—urinary bladder cancer	7.83e-05	0.000494	CcSEcCtD
Amsacrine—Paraesthesia—Methotrexate—urinary bladder cancer	7.74e-05	0.000488	CcSEcCtD
Amsacrine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—urinary bladder cancer	7.73e-05	0.000487	CcSEcCtD
Amsacrine—Anorexia—Epirubicin—urinary bladder cancer	7.69e-05	0.000485	CcSEcCtD
Amsacrine—Dyspnoea—Methotrexate—urinary bladder cancer	7.68e-05	0.000484	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	7.66e-05	0.0011	CbGpPWpGaD
Amsacrine—Hypotension—Epirubicin—urinary bladder cancer	7.54e-05	0.000475	CcSEcCtD
Amsacrine—Confusional state—Doxorubicin—urinary bladder cancer	7.53e-05	0.000474	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—EP300—urinary bladder cancer	7.52e-05	0.00108	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CCNE1—urinary bladder cancer	7.5e-05	0.00108	CbGpPWpGaD
Amsacrine—Decreased appetite—Methotrexate—urinary bladder cancer	7.49e-05	0.000472	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Methotrexate—urinary bladder cancer	7.44e-05	0.000469	CcSEcCtD
Amsacrine—Fatigue—Methotrexate—urinary bladder cancer	7.43e-05	0.000468	CcSEcCtD
Amsacrine—Infection—Doxorubicin—urinary bladder cancer	7.41e-05	0.000467	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	7.41e-05	0.00106	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	7.39e-05	0.00106	CbGpPWpGaD
Amsacrine—Pain—Methotrexate—urinary bladder cancer	7.37e-05	0.000465	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—TYMS—urinary bladder cancer	7.36e-05	0.00106	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—SRC—urinary bladder cancer	7.31e-05	0.00105	CbGpPWpGaD
Amsacrine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	7.31e-05	0.000461	CcSEcCtD
Amsacrine—Tachycardia—Doxorubicin—urinary bladder cancer	7.28e-05	0.000459	CcSEcCtD
Amsacrine—ABCB1—Transmembrane transport of small molecules—SLC14A2—urinary bladder cancer	7.26e-05	0.00104	CbGpPWpGaD
Amsacrine—Skin disorder—Doxorubicin—urinary bladder cancer	7.25e-05	0.000457	CcSEcCtD
Amsacrine—Paraesthesia—Epirubicin—urinary bladder cancer	7.24e-05	0.000457	CcSEcCtD
Amsacrine—Dyspnoea—Epirubicin—urinary bladder cancer	7.19e-05	0.000453	CcSEcCtD
Amsacrine—Anorexia—Doxorubicin—urinary bladder cancer	7.11e-05	0.000448	CcSEcCtD
Amsacrine—Feeling abnormal—Methotrexate—urinary bladder cancer	7.1e-05	0.000448	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—PTEN—urinary bladder cancer	7.1e-05	0.00102	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	7.05e-05	0.00101	CbGpPWpGaD
Amsacrine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	7.05e-05	0.000444	CcSEcCtD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	7.04e-05	0.00101	CbGpPWpGaD
Amsacrine—Decreased appetite—Epirubicin—urinary bladder cancer	7.01e-05	0.000442	CcSEcCtD
Amsacrine—Hypotension—Doxorubicin—urinary bladder cancer	6.97e-05	0.00044	CcSEcCtD
Amsacrine—Gastrointestinal disorder—Epirubicin—urinary bladder cancer	6.96e-05	0.000439	CcSEcCtD
Amsacrine—Fatigue—Epirubicin—urinary bladder cancer	6.95e-05	0.000438	CcSEcCtD
Amsacrine—NCOA3—Metabolism—GSTP1—urinary bladder cancer	6.94e-05	0.000997	CbGpPWpGaD
Amsacrine—Pain—Epirubicin—urinary bladder cancer	6.9e-05	0.000435	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	6.85e-05	0.000985	CbGpPWpGaD
Amsacrine—Urticaria—Methotrexate—urinary bladder cancer	6.85e-05	0.000432	CcSEcCtD
Amsacrine—Abdominal pain—Methotrexate—urinary bladder cancer	6.81e-05	0.000429	CcSEcCtD
Amsacrine—Body temperature increased—Methotrexate—urinary bladder cancer	6.81e-05	0.000429	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—EP300—urinary bladder cancer	6.77e-05	0.000972	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.71e-05	0.000964	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CCNE1—urinary bladder cancer	6.7e-05	0.000963	CbGpPWpGaD
Amsacrine—Paraesthesia—Doxorubicin—urinary bladder cancer	6.7e-05	0.000422	CcSEcCtD
Amsacrine—TOP2A—Azacitidine—Gemcitabine—urinary bladder cancer	6.69e-05	0.0134	CbGdCrCtD
Amsacrine—Dyspnoea—Doxorubicin—urinary bladder cancer	6.65e-05	0.000419	CcSEcCtD
Amsacrine—Feeling abnormal—Epirubicin—urinary bladder cancer	6.65e-05	0.000419	CcSEcCtD
Amsacrine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	6.6e-05	0.000416	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle—TYMS—urinary bladder cancer	6.58e-05	0.000946	CbGpPWpGaD
Amsacrine—KCNH2—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	6.5e-05	0.000933	CbGpPWpGaD
Amsacrine—Decreased appetite—Doxorubicin—urinary bladder cancer	6.49e-05	0.000409	CcSEcCtD
Amsacrine—NCOA3—Metabolism—TYMS—urinary bladder cancer	6.45e-05	0.000927	CbGpPWpGaD
Amsacrine—Gastrointestinal disorder—Doxorubicin—urinary bladder cancer	6.44e-05	0.000406	CcSEcCtD
Amsacrine—Fatigue—Doxorubicin—urinary bladder cancer	6.43e-05	0.000406	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—urinary bladder cancer	6.41e-05	0.000921	CbGpPWpGaD
Amsacrine—Urticaria—Epirubicin—urinary bladder cancer	6.41e-05	0.000404	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—EGFR—urinary bladder cancer	6.41e-05	0.00092	CbGpPWpGaD
Amsacrine—Pain—Doxorubicin—urinary bladder cancer	6.38e-05	0.000402	CcSEcCtD
Amsacrine—NCOA3—Metabolism—NCOR1—urinary bladder cancer	6.38e-05	0.000916	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—GSTM1—urinary bladder cancer	6.38e-05	0.000916	CbGpPWpGaD
Amsacrine—Body temperature increased—Epirubicin—urinary bladder cancer	6.38e-05	0.000402	CcSEcCtD
Amsacrine—Abdominal pain—Epirubicin—urinary bladder cancer	6.38e-05	0.000402	CcSEcCtD
Amsacrine—Hypersensitivity—Methotrexate—urinary bladder cancer	6.35e-05	0.0004	CcSEcCtD
Amsacrine—Asthenia—Methotrexate—urinary bladder cancer	6.18e-05	0.00039	CcSEcCtD
Amsacrine—Feeling abnormal—Doxorubicin—urinary bladder cancer	6.15e-05	0.000388	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	6.14e-05	0.000882	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—GPX1—urinary bladder cancer	6.11e-05	0.000877	CbGpPWpGaD
Amsacrine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	6.1e-05	0.000385	CcSEcCtD
Amsacrine—NCOA3—Developmental Biology—TNF—urinary bladder cancer	6.1e-05	0.000876	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—KRAS—urinary bladder cancer	6.05e-05	0.000869	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	6.01e-05	0.000863	CbGpPWpGaD
Amsacrine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—MYC—urinary bladder cancer	6.01e-05	0.000863	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—ERCC2—urinary bladder cancer	6e-05	0.000861	CbGpPWpGaD
Amsacrine—Hypersensitivity—Epirubicin—urinary bladder cancer	5.94e-05	0.000375	CcSEcCtD
Amsacrine—Urticaria—Doxorubicin—urinary bladder cancer	5.93e-05	0.000374	CcSEcCtD
Amsacrine—Abdominal pain—Doxorubicin—urinary bladder cancer	5.9e-05	0.000372	CcSEcCtD
Amsacrine—Body temperature increased—Doxorubicin—urinary bladder cancer	5.9e-05	0.000372	CcSEcCtD
Amsacrine—Diarrhoea—Methotrexate—urinary bladder cancer	5.9e-05	0.000372	CcSEcCtD
Amsacrine—Asthenia—Epirubicin—urinary bladder cancer	5.79e-05	0.000365	CcSEcCtD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDK4—urinary bladder cancer	5.74e-05	0.000825	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TERT—urinary bladder cancer	5.73e-05	0.000824	CbGpPWpGaD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	5.72e-05	0.000822	CbGpPWpGaD
Amsacrine—Dizziness—Methotrexate—urinary bladder cancer	5.7e-05	0.000359	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	5.68e-05	0.000815	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—MTHFR—urinary bladder cancer	5.64e-05	0.000809	CbGpPWpGaD
Amsacrine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	5.52e-05	0.000793	CbGpPWpGaD
Amsacrine—Diarrhoea—Epirubicin—urinary bladder cancer	5.52e-05	0.000348	CcSEcCtD
Amsacrine—Hypersensitivity—Doxorubicin—urinary bladder cancer	5.5e-05	0.000347	CcSEcCtD
Amsacrine—ABCB1—Allograft Rejection—CXCL8—urinary bladder cancer	5.48e-05	0.000788	CbGpPWpGaD
Amsacrine—Vomiting—Methotrexate—urinary bladder cancer	5.48e-05	0.000345	CcSEcCtD
Amsacrine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	5.44e-05	0.000782	CbGpPWpGaD
Amsacrine—Rash—Methotrexate—urinary bladder cancer	5.43e-05	0.000343	CcSEcCtD
Amsacrine—ABCB1—HIF-1-alpha transcription factor network—EP300—urinary bladder cancer	5.43e-05	0.00078	CbGpPWpGaD
Amsacrine—Dermatitis—Methotrexate—urinary bladder cancer	5.43e-05	0.000342	CcSEcCtD
Amsacrine—Headache—Methotrexate—urinary bladder cancer	5.4e-05	0.00034	CcSEcCtD
Amsacrine—Asthenia—Doxorubicin—urinary bladder cancer	5.35e-05	0.000338	CcSEcCtD
Amsacrine—Dizziness—Epirubicin—urinary bladder cancer	5.33e-05	0.000336	CcSEcCtD
Amsacrine—ABCB1—Transmembrane transport of small molecules—AQP3—urinary bladder cancer	5.25e-05	0.000754	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—IL2—urinary bladder cancer	5.24e-05	0.000753	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—ATM—urinary bladder cancer	5.15e-05	0.00074	CbGpPWpGaD
Amsacrine—NCOA3—Developmental Biology—HRAS—urinary bladder cancer	5.14e-05	0.000739	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDK4—urinary bladder cancer	5.13e-05	0.000737	CbGpPWpGaD
Amsacrine—Vomiting—Epirubicin—urinary bladder cancer	5.13e-05	0.000323	CcSEcCtD
Amsacrine—Nausea—Methotrexate—urinary bladder cancer	5.12e-05	0.000323	CcSEcCtD
Amsacrine—Diarrhoea—Doxorubicin—urinary bladder cancer	5.11e-05	0.000322	CcSEcCtD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CCNE1—urinary bladder cancer	5.1e-05	0.000732	CbGpPWpGaD
Amsacrine—Rash—Epirubicin—urinary bladder cancer	5.09e-05	0.000321	CcSEcCtD
Amsacrine—Dermatitis—Epirubicin—urinary bladder cancer	5.08e-05	0.00032	CcSEcCtD
Amsacrine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	5.07e-05	0.000729	CbGpPWpGaD
Amsacrine—Headache—Epirubicin—urinary bladder cancer	5.05e-05	0.000319	CcSEcCtD
Amsacrine—TOP2A—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	5.04e-05	0.000725	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TYMS—urinary bladder cancer	5.01e-05	0.000719	CbGpPWpGaD
Amsacrine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	5e-05	0.000719	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—RB1—urinary bladder cancer	4.99e-05	0.000717	CbGpPWpGaD
Amsacrine—Dizziness—Doxorubicin—urinary bladder cancer	4.94e-05	0.000311	CcSEcCtD
Amsacrine—TOP2A—Circadian rythm related genes—TP53—urinary bladder cancer	4.84e-05	0.000696	CbGpPWpGaD
Amsacrine—Nausea—Epirubicin—urinary bladder cancer	4.79e-05	0.000302	CcSEcCtD
Amsacrine—Vomiting—Doxorubicin—urinary bladder cancer	4.75e-05	0.000299	CcSEcCtD
Amsacrine—Rash—Doxorubicin—urinary bladder cancer	4.71e-05	0.000297	CcSEcCtD
Amsacrine—Dermatitis—Doxorubicin—urinary bladder cancer	4.7e-05	0.000296	CcSEcCtD
Amsacrine—Headache—Doxorubicin—urinary bladder cancer	4.68e-05	0.000295	CcSEcCtD
Amsacrine—NCOA3—Metabolism—PPARG—urinary bladder cancer	4.57e-05	0.000656	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—RB1—urinary bladder cancer	4.46e-05	0.000641	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—FAS—urinary bladder cancer	4.44e-05	0.000637	CbGpPWpGaD
Amsacrine—Nausea—Doxorubicin—urinary bladder cancer	4.43e-05	0.000279	CcSEcCtD
Amsacrine—NCOA3—Metabolism—CREBBP—urinary bladder cancer	4.39e-05	0.000631	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN2A—urinary bladder cancer	4.39e-05	0.00063	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—TRPV1—urinary bladder cancer	4.28e-05	0.000615	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN2A—urinary bladder cancer	3.92e-05	0.000564	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—ATM—urinary bladder cancer	3.92e-05	0.000563	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—urinary bladder cancer	3.9e-05	0.000561	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—urinary bladder cancer	3.89e-05	0.000559	CbGpPWpGaD
Amsacrine—ABCB1—Allograft Rejection—TNF—urinary bladder cancer	3.82e-05	0.000548	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CCND1—urinary bladder cancer	3.71e-05	0.000532	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PTGS2—urinary bladder cancer	3.59e-05	0.000516	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GSTZ1—urinary bladder cancer	3.59e-05	0.000515	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—CDKN1A—urinary bladder cancer	3.59e-05	0.000515	CbGpPWpGaD
Amsacrine—KCNH2—Neuronal System—HRAS—urinary bladder cancer	3.44e-05	0.000494	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—EP300—urinary bladder cancer	3.41e-05	0.00049	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CREBBP—urinary bladder cancer	3.41e-05	0.000489	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GSTO2—urinary bladder cancer	3.4e-05	0.000489	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NAT1—urinary bladder cancer	3.4e-05	0.000489	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	3.38e-05	0.000486	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—IGF1—urinary bladder cancer	3.37e-05	0.000483	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CCND1—urinary bladder cancer	3.31e-05	0.000476	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—CDKN1A—urinary bladder cancer	3.21e-05	0.000461	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	3.21e-05	0.00046	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	3.21e-05	0.00046	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—PTEN—urinary bladder cancer	3.14e-05	0.00045	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—UGT2B7—urinary bladder cancer	3.11e-05	0.000447	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—EP300—urinary bladder cancer	3.05e-05	0.000438	CbGpPWpGaD
Amsacrine—NCOA3—Metabolism—EP300—urinary bladder cancer	2.99e-05	0.000429	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle, Mitotic—MYC—urinary bladder cancer	2.97e-05	0.000427	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	2.93e-05	0.000421	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—TFRC—urinary bladder cancer	2.89e-05	0.000415	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—urinary bladder cancer	2.85e-05	0.00041	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CYP4B1—urinary bladder cancer	2.8e-05	0.000402	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—urinary bladder cancer	2.79e-05	0.000401	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—MYC—urinary bladder cancer	2.66e-05	0.000382	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—SLC19A1—urinary bladder cancer	2.65e-05	0.00038	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	2.64e-05	0.000379	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PRSS3—urinary bladder cancer	2.58e-05	0.00037	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CCND1—urinary bladder cancer	2.52e-05	0.000362	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	2.49e-05	0.000358	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1A—urinary bladder cancer	2.44e-05	0.00035	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—urinary bladder cancer	2.43e-05	0.00035	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	2.43e-05	0.000349	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—urinary bladder cancer	2.32e-05	0.000333	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—SRC—urinary bladder cancer	2.26e-05	0.000324	CbGpPWpGaD
Amsacrine—TOP2A—Cell Cycle—TP53—urinary bladder cancer	2.18e-05	0.000314	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—TYMP—urinary bladder cancer	2.06e-05	0.000296	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—MYC—urinary bladder cancer	2.02e-05	0.00029	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—urinary bladder cancer	1.98e-05	0.000284	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	1.94e-05	0.000279	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TNF—urinary bladder cancer	1.88e-05	0.000271	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—urinary bladder cancer	1.87e-05	0.000268	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NAT2—urinary bladder cancer	1.86e-05	0.000268	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	1.76e-05	0.000252	CbGpPWpGaD
Amsacrine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—urinary bladder cancer	1.66e-05	0.000239	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—RRM2—urinary bladder cancer	1.61e-05	0.000231	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	1.52e-05	0.000218	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—ENO2—urinary bladder cancer	1.49e-05	0.000214	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—HPGDS—urinary bladder cancer	1.49e-05	0.000214	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GSTT1—urinary bladder cancer	1.45e-05	0.000208	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	1.4e-05	0.000202	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	1.4e-05	0.000202	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	1.36e-05	0.000196	CbGpPWpGaD
Amsacrine—ABCB1—Transmembrane transport of small molecules—CREBBP—urinary bladder cancer	1.35e-05	0.000194	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NQO1—urinary bladder cancer	1.2e-05	0.000173	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	1.13e-05	0.000163	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GSTP1—urinary bladder cancer	1e-05	0.000144	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	9.44e-06	0.000136	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—TYMS—urinary bladder cancer	9.31e-06	0.000134	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—NCOR1—urinary bladder cancer	9.21e-06	0.000132	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GSTM1—urinary bladder cancer	9.21e-06	0.000132	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—GPX1—urinary bladder cancer	8.82e-06	0.000127	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	8.78e-06	0.000126	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	8.67e-06	0.000125	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	8.67e-06	0.000125	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—ERCC2—urinary bladder cancer	8.65e-06	0.000124	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	8.31e-06	0.000119	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	8.16e-06	0.000117	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—MTHFR—urinary bladder cancer	8.14e-06	0.000117	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	7.67e-06	0.00011	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PPARG—urinary bladder cancer	6.6e-06	9.48e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—CREBBP—urinary bladder cancer	6.34e-06	9.1e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	6.22e-06	8.93e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	5.97e-06	8.58e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PTGS2—urinary bladder cancer	5.19e-06	7.45e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	4.89e-06	7.02e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—PTEN—urinary bladder cancer	4.53e-06	6.5e-05	CbGpPWpGaD
Amsacrine—ABCB1—Metabolism—EP300—urinary bladder cancer	4.32e-06	6.2e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	4.26e-06	6.13e-05	CbGpPWpGaD
Amsacrine—CYP2D6—Metabolism—EP300—urinary bladder cancer	4.07e-06	5.84e-05	CbGpPWpGaD
